San Francisco startup Construction Therapeutics is also focusing on an oral, the moment-every day GLP-1 drug called GSBR-1290—the drug surpassed Wall Street’s expectations in June whenever a mid-stage review confirmed normal weight loss of around six% and it programs to start another